GlassScriptPhysician profile
Chakri Gavva
NPI 1821432089
$1,357.84
in general payments reported to CMS, 2019-2025
15 companies · $492 in 2025
The $492 reported for 2025 was more than what 86% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $37.52 · 2021: $101 · 2022: $391 · 2023: $65.85 · 2024: $89.02 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $278.49 | 2019-2024 | Injectafer |
| Genzyme Corporation | $263.73 | 2022-2025 | |
| Werfen USA LLC | $173.36 | 2025 | |
| Alexion Pharmaceuticals, INC. | $153.46 | 2022-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $121.19 | 2023-2025 | Monoferric |
| Haemonetics Corporation | $101.36 | 2021 | |
| Amgen INC. | $54.08 | 2022-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $46.01 | 2019-2020 | |
| Grifols USA, LLC | $34.91 | 2022 | |
| Lilly USA, LLC | $25.39 | 2024 | Kisunla |
| Astrazeneca Pharmaceuticals LP | $23.89 | 2022 | |
| Eisai INC. | $22.40 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.12 | 2020 | |
| Janssen Biotech, INC. | $19.67 | 2025 | Tremfya |
| Shire North American Group INC | $18.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chakri Gavva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.